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MIKROENKAPSULASI DAN PENGGUNAAN EKSTRAK CATHA EDULIS 
TERHADAP TINGKAHLAKU SEKSUAL, BERAT BADAN DAN PROFIL 
LIPID DARAH DALAM TIKUS 
 
ABSTRAK 
 
Catha edulis (CE) yang biasa dikenali sebagai khat telah dilaporkan dapat 
meningkatkan motivasi seksual dan mempunyai kesan anti-obesiti. Khat secara 
tradisional diambil melalui pengunyahan daunnya diikuti dengan penelanan 
perlahan-lahan jus untuk kesan yang dikehendaki. Kajian ini bertujuan untuk meniru 
pelepasan bertahan kandungan khat melalui penyediaan mikrokapsul pelepasan 
bertahan ekstrak khat. Kesan ekstrak khat dan mikrokapsul pelepasan bertahan 
terhadap motivasi seksual, rembesan vagina, paras estradiol, pengambilan makanan, 
berat badan, paras kolesterol dan trigliserida pada tikus telah diperiksa. Gelatin 
digunakan untuk menyediakan mikrokapsul tetapi ia tidak dapat enkapsulat sebatian 
teras yang larut air, seperti pseudoefedrin HCl, verapamil HCl, propranolol HCl dan 
parasetamol serta campuran parasetamol dan pseudoefedrin HCl. Dengan itu, 
ovalbumin dimasukkan untuk sebatian teras yang larut air. Ovalbumin dapat 
bertindak sebagai lapisan pelindung di antara teras sebatian dan salutan gelatin, 
menghalang partisi teras sebatian larut air keluar dari mikrokapsul. Di samping itu, 
salutan ovalbumin-gelatin dapat melambatkan pelepasan drug. Ovalbumin-gelatin 
seterusnya digunakan untuk menyediakan mikrokapsul ekstrak khat. Mikrokapsul 
khat-ovalbumin-gelatin meningkatkan motivasi seksual, estradiol, dan rembesan 
vagina tikus betina. Pengambilan oral ekstrak khat didapati mengurangkan berat 
badan, pengambilan makanan, paras kolesterol dan trigliserida darah tikus, dan 
 xxiv 
kesannya dapat bertahan selama satu minggu. Apabila ekstrak khat diformulasi 
sebagai mikrokapsul, kesan dapat dipanjangkan ke tiga minggu. Kesan itu berlarutan 
sehingga 8 minggu tanpa pemerhatian “rebound”, apabila mikrokapsul diberikan 
sebagai suntikan subkutaneus. Memperlambatkan pelepasan ekstrak khat berkorelasi 
secara langsung dengan pengurangan berat badan, paras kolesterol dan trigliserida 
darah. Suntikan subkutaneus lebih berkesan daripada pemberian oral untuk ekstrak 
khat. Kesan ekstrak khat dalam mengurangkan paras kolesterol dan trigliserida 
darah, ditingkatkan lagi apabila digabungkan dengan ekstrak bawang putih. Kesan 
ini mungkin disebabkan oleh sifat pengemulsian ekstrak garlik dan aktiviti lipolisis 
ekstrak khat. Secara kesimpulan, pelepasan bertahan mikroenkapsulasi ekstrak khat 
mungkin kaedah yang berkesan untuk merawat keinginan seksual hipoaktif dalam 
perempuan dan mengurangkan berat badan dan profil lipid manusia. 
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MICROENCAPSULATION AND APPLICATION OF CATHA EDULIS 
EXTRACT ON SEXUAL BEHAVIOUR, BODY WEIGHT AND BLOOD 
LIPID PROFILES IN RATS 
 
ABSTRACT 
 
Catha edulis (CE) which is commonly known as khat has been reported to improve 
sexual motivation and has anti-obesity property. Khat is traditionally consumed via 
chewing of the leaf followed by slowly swallowing the juices for the desired effect. 
This study aimed to simulate the sustained release of khat content through the 
preparation of sustained release microcapsules of khat extract. The effect of khat 
extract and the sustained release microcapsules on the sexual motivation, vaginal 
secretions, estradiol levels, food intake, body weight, blood cholesterol and 
triglycerides levels was examined in rats. Gelatin was used to prepare the 
microcapsules but it was not able to encapsulate water soluble core compounds, such 
as pseudoephedrine HCl, verapamil HCl, propranolol HCl and paracetamol as well as 
a mixture of paracetamol and pseudoephedrine HCl. In this regard, ovalbumin was 
incorporated for soluble core compounds. Ovalbumin could act as a protective layer 
between the core material and the gelatin coating, preventing the partitioning of the 
soluble core compound out of the microcapsules. Moreover, the ovalbumin-gelatin 
coat could sustain the release of drug. The ovalbumin-gelatin was subsequently used 
to prepare khat extract microcapsules. The khat-ovalbumin-gelatin microcapsules 
enhanced sexual motivation, up-regulated estradiol, and increased vaginal secretions 
in female rats. Oral administration of khat extract was found to reduce the body 
weight, food intake, blood cholesterol and triglyceride levels of rats, and the effect 
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could last for one week. When khat extract was formulated as microcapsules, the 
effect was extended to three weeks. The effect was extended further to 8 weeks 
without observation of rebound, when the microcapsules were given as subcutaneous 
injection. Sustaining the release of khat extract correlated directly with the reduction 
in body weight, blood cholesterol and triglyceride levels. The subcutaneous injection 
was more effective than the oral route for khat extract administration. The effect of 
khat extract in reducing blood cholesterol and triglyceride levels was further 
enhanced when combined with garlic extract. The mechanism could be attributed to 
the emulsifying property of garlic extract and the lipolysis activity of khat extract. In 
conclusion, control release of the microencapsulated khat extract might be an 
effective means for treating hypoactive sexual desire of females and reducing the 
body weight and lipid profiles in human. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 BACKGROUND  
Sexual health is important to overall good health and well-being (Mulhall et al., 
2008). Recently, female sexual dysfunction has attracted much interest in the field of 
medical sciences (Clayton, 2007; Aslan et al., 2008; Both et al., 2008a; Both et al., 
2008b; Derogatis and Burnett, 2008; Garcia et al., 2008; Harte and Meston, 2008; 
Hayes et al., 2008; Laan et al., 2008). Female sexual dysfunction, which consists of 
multiple disorders, are categorized as hypoactive sexual desire disorder, orgasmic 
disorder, sexual arousal disorder, and sexual pain disorder (Berman et al., 1999; 
Goldstein et al., 2000; Traish et al., 2004; Clayton, 2007; Aslan et al., 2008; Beharry 
et al., 2008; Derogatis and Burnett, 2008). Female sexual arousal disorder refers to a 
lack of responsiveness to sexual stimulation in women (Wincze and Carey, 2001).   
 
Obesity and overweight are the most important risk factor contributing to the overall 
burden of disease worldwide (Flint et al., 2010; Khan et al., 2010; Sato et al., 2010). 
The identification of the biochemical basis for hunger and meal initiation, and of the 
signals controlling these neurobiological processes have been the subject of 
extensive research and debate for some decades regarding the control of food intake 
(Chaput and Tremblay, 2009). 
 
Many natural herbs are purported either to enhance libido or to treat obesity. One of 
such plants, commonly known as khat (Catha edulis) is thought to affect libido 
and/or anorexia. Its positive effects occur when khat is chewed. 
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1.2 KHAT (CATHA EDULIS) 
Khat, Catha edulis Forsk, an evergreen shrub or tree, belongs to the suborder 
Rosidae and family Celastraceae. The cultivation areas of khat are in Ethiopia, 
Yemen, Kenya, South Africa, Uganda, Tanzania, Rwanda, Zimbabwe, Turkistan, 
Afghanistan and northern Hejaz. It is cultivated at an altitude of 1670–2590 meters 
and can live up to 75–100 years if taken care properly (Al-Hebshi and Skaug, 2005). 
Other khat names reported were tchat, qat, qaad/jaad, miraa, mairungi, muhulo, cat, 
catha, gat, tohai, muraa, Abyssinian tea or Arabian tea (Feyissa and Kelly, 2008). 
  
1.2.1 ACTIVE CONSTITUENTS OF KHAT 
The chemical constituents of khat leaf include alkaloids, terpenoids, flavonoids, 
sterols, glycosides, tannins, amino acids, vitamins and minerals (Feyissa and Kelly, 
2008; Pennings et al., 2008). The major alkaloids in fresh khat leave of various 
origins are cathinone, cathine and norephedrine at 0.95, 1.98, and 0.54 mg/g of khat 
leaf, respectively (Geisshüsler and Brenneisen, 1987; Kalix, 1990; Widler et al., 
1994; Dimba et al., 2004; Feyissa and Kelly, 2008). The major contents of adult or 
dry khat leaves are cathine and norephedrine at an approximate ratio of 4:1 (Schorno 
and Steinegger, 1979; Kalix, 1990; Sporkert et al., 2003; Feyissa and Kelly, 2008). 
Cathinone is unstable and undergoes decomposition to relatively inactive compounds 
after harvesting and during drying or extraction of the plant material (Pennings et al., 
2008).  
 
1.2.2 TRADITIONAL MODE OF KHAT ADMINISTRATION 
Several million people are habitual khat users and khat chewing is predominantly a 
male habit. However, female’s habit is less and smaller quantities of khat are chewed 
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for shorter periods (Al-Motarreb et al., 2002b; Al-Hebshi and Skaug, 2005). 
Chewing of khat leaves is a common practice during social gatherings in the local 
populations that often last for several hours (Kassie et al., 2001; Al-Motarreb et al., 
2002b). After the first few hours of consumption, users of khat demonstrate 
increased alertness, better self-esteem, augmented feeling of elation, enhanced 
imaginative ability, and improved capacity to relate ideas (Cox and Rampes, 2003). 
However, towards the end of the khat session, some users experience a depressive 
stage often manifested as irritability, anorexia, hyperthermia, insomnia, mydriasis, 
and endocrine disturbances (Al-Motarreb et al., 2002b; Hassan et al., 2002). 
 
The mastication of khat leaves is the exclusive method of khat use. However, khat 
(dry leaves) is rarely used as tea (namely Abyssinian or Arabian tea) in close 
connection with the use of coffee. The khat chewing habit has a deep rooted social 
and cultural tradition. Khat is usually chewed at special social gatherings, but is also 
used frequently during work to keep alert and reduce physical fatigue. The way of 
khat use is described by chewing the 100–200 g of khat leaves one by one for 
duration of 2-4 h. During mastication, the juice is swallowed while the residue is 
stored in cheek (Al-Hebshi and Skaug, 2005; Feyissa and Kelly, 2008; Pennings et 
al., 2008).  
 
Chewing khat leaves in traditional manner results in enhancement of some activities 
as well as diminished side effects (Cox and Rampes, 2003; Toennes et al., 2003; 
Feyissa and Kelly, 2008). A habitual user masticates the leaves slowly one by one, 
librating alkaloids consistently and slowly swallowing the juice during the khat 
session period of 3-4 hours. Hence, special emphasis on the sustained release of 
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alkaloids consistently from khat leaves could be obtained from the traditional way of 
khat consumption by chewing. 
   
1.2.3 HABITUAL OR ADDICTIVE PROPERTY OF KHAT 
Khat was described by several studies as a habitual substance (Al-Motarreb et al., 
2002b; Numan, 2004; Al-Hebshi and Skaug, 2005; Feyissa and Kelly, 2008; 
Pennings et al., 2008). A recent review by Pennings et al. (2008) on the physical and 
psychological dependence liability of khat reported that pure cathinone had an 
addictive potential due to the fast onset of action when administered parenterally. 
However, khat leave was not classified as drug dependence due to the self-limiting 
way of administration by chewing. It was concluded that khat has low abuse 
potential in human and khat dependence is mild. Furthermore, Al-Motarreb et al. 
(2002b) reported that mild craving and tolerance to the effect of khat do exist but 
there is no definite withdrawal syndrome. Withdrawal symptoms after prolonged use 
may consist of lethargy, mild depression, slight trembling and recurrent bad dreams 
(Kalix, 1988), but these symptoms are mild and resolve in a short time (Kalix, 1990). 
Another recent review by Feyissa and Kelly (2008) reported that the habitual use of 
khat is in many instances compulsive, as indicated by the tendency of khat chewers 
to secure their daily supply of the leaves at the expense of vital needs (Kalix and 
Braenden, 1985; Nencini et al., 1988). This is described as a psychological 
dependence by many authors (Kalix, 1990; Gosnell et al., 1996; Connor et al., 2002). 
In eastern African countries, the prevalence of khat dependence is estimated to be 5–
15% of the population (Nielen et al., 2004). The review concluded that generally it is 
believed that there is no physical withdrawal symptoms occur in khat users, as 
experienced with alcohol, morphine or barbiturates (Luqman and Danowski, 1975; 
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Kalix, 1984; Al-Motarreb et al., 2002b; Sulzer et al., 2005). Abandoning the khat 
chewing habit however is followed by symptoms including lassitude, nightmares, 
slight trembling, and depression (Luqman and Danowski, 1975; Elmi, 1983; Alem et 
al., 1999; Cox and Rampes, 2003). Indeed, habitual users report that they have no 
serious difficulties when moving to an area where khat cannot be obtained (Kalix, 
1990).  
 
1.2.4 SEXUAL BEHAVIOR EFFECT OF KHAT  
The early reports on the sexual activity of khat were reported in 1959 by Dr. 
Kervingant and Dr. Trellu, United Nations Office on Drug and Crime (UNODC) 
(Kervingant, 1959; Trellu, 1959). Kervingant (1959) reported that khat is an 
aphrodisiac. Trellu (1959) reported that khat acts like coffee, which is one of the 
most potent aphrodisiacs.  
 
The report of Halbach (1972) documented that khat was an aphrodisiac. Initially, it 
increased libido but spermatorrhoea and subsequently impotence might occur with 
chronic use of khat. Luqman and Danowski (1975) reported that khat is an 
aphrodisiac which enhances sexual activity in the depressed person. Khat chewing 
delays the ejaculation phase, which treats premature ejaculation. However, a 
spontaneous secretion of spermatic fluid may occur in many khat chewers, when khat 
exacerbates or accentuates anxiety states. On the other hand, the advisory group of 
WHO reported that the chronic administration of khat is believed to have 
spermatorrhoea effect in males (Chanoit et al., 1980). 
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Elmi (1983) conducted an epidemiological research on khat to estimate its 
prevalence, social characteristics of consumers, patterns of use and effects during and 
after consumption. Consumers and non-consumers (7485 people) were randomly 
interviewed. The results showed that about 60% of the male population reported 
increase of libido which was not sustained by an equal increase of sexual potency 
and 18.78% reported improvement of sexual performance, while 61% denounced its 
impairment. The situation in the female population was very different; the increase of 
sexual desire (71.72%) was in fact followed by improvement of performance ability 
(78.26%). Sixty one percent of the male population reported either spermathorroea or 
precocious ejaculation. 
 
Islam et al. (1990) investigated the reproductive toxicity of a chemically synthesized 
(-)-cathinone on male rats. Three dose levels of cathinone were administered 
intraperitoneally as 5, 10 and 30 mg/kg body weight of rats to assess their 
reproductive toxicity. The results showed that cathinone produced a dose-dependent 
decrease in sperm count and increased the number of abnormal sperms. Furthermore, 
the plasma testosterone was also decreased. 
 
Taha et al. (1995) studied the effect of (-)-cathinone, caffeine and their combinations 
on the sexual behaviour of male rats. Male sexual activities were assessed by 
recording the erectile responses (grooming of genitalis, stretching and homosexual 
mounting), in the absence of females. The copulatory behaviour was observed by 
caging males with receptive females brought into oestrus with subcutaneous injection 
of oestradiol benzoate and progesterone. The copulatory pattern of male rats 
(mounting, intromissions, ejaculations and refractory period) was recorded. The 
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results showed that the oral treatment of the combination of cathinone and caffeine (5 
and 50 mg/kg/day) for 15 days increased sexual arousal (motivation) in male rats 
(increased mounting performance and anogenital investigatory behaviour with no 
stimulatory effect on erectile and ejaculatory responses). 
 
Adeoya-Osiguwa and Fraser (2005) investigated the effects of cathine and 
norephedrine on the function of mammalian uncapacitated sperm suspensions using 
mouse and human spermatozoa. The result showed that cathine and norephedrine 
significantly accelerated capacitation and the treated sperm suspensions were 
significantly more fertile than controls. The study concluded that cathine and 
norephedrine can directly affect mammalian sperm function, accelerating 
capacitation and inhibiting spontaneous acrosome reactions. It was suggested that 
cathine and norephedrine, at appropriate doses, might enhance fertility. 
 
Mwenda et al. (2006) determined the effects of oral administration of crude khat 
juice extract on the circulating hormones of male Olive Baboon (Papio anubis, 
Cercopithecidae) for 1 and 2 months. The results showed that khat administration 
(fresh juice made of khat leaves and peeled bark) to male baboon (250g/50 
mL/baboon) caused a significant increase in the mean testosterone levels, while 
prolactin and cortisol levels were reduced. These effects were also evident 1 month 
post treatment, indicating that khat may exert a transient effect on male fertility by 
interfering with the hormonal profiles. 
 
Abdulwaheb et al. (2007) evaluated the effect of oral administration of khat extract 
on sexual behavior in male rats. Adult albino Wistar male rats were administered 
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khat extracts (100, 200, 400 mg/kg), amphetamine (1 mg/kg), sildenafil (1 mg/kg), 
ethanol (2 mL/kg of 2% and 10%), and combination of khat and ethanol (2% + 10%) 
for 15 days. The results showed that rats treated with 400 mg/kg of khat 
demonstrated a statistically significant increase in all sexual parameters except in 
mounting frequency, intercopulatory interval and copulatory efficiency. Whereas, 
rats treated with 200 mg/kg showed a statistically significant increase only in 
ejaculation latency. In contrast, low dose of khat extract at 100 mg/kg was found to 
significantly reduce both intromission latency and mount latency, thereby enhancing 
sexual motivation/arousal in male rats. Similar results were obtained when khat 
extract (200 mg/kg) and ethanol (10%) were administered concomitantly despite the 
inhibitory effect observed in male sexual behavior when administered alone. The 
study concluded that higher doses of the extract inhibited sexual behavior in male 
rats. In contrast, low dose of the extract as well as the concurrent administration of 
the extract followed by ethanol was found to enhance male rat sexual 
motivation/arousal. 
 
Nyongesa et al. (2007) investigated the in-vitro effect of khat extract on mouse 
interstitial cells. The isolated mouse interstitial cells were incubated with different 
concentration of khat extract (0.06, 0.6, 6.0, 30.0 and 60 mg/mL). Testosterone level 
was measured at 30-min intervals over 3 h of incubation period. The results showed 
that khat extract at high concentration (30 and 60 mg/mL) inhibited testosterone 
production, while low concentration (0.06, 0.6 and 6 mg/mL) stimulated testosterone 
production. The study assumed that khat extract at high concentration might cause 
impairment of reproductive function but at low concentration might enhance 
reproductive functions. 
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Nyongesa et al. (2008) investigated the effect of fresh khat extract on luteinizing 
hormone in male rabbits. The rabbits were divided into five groups. One group 
served as control fed with normal saline, and four groups fed with khat extract (1.5, 
4.5, 13.5 and 40.5 g/kg) twice a week for 5 weeks. The results showed that all doses 
of khat extract lowered plasma luteinizing hormone and plasma testosterone levels. 
However, plasma cortisol levels were elevated in a dose-dependent manner. The 
study assumed that khat may impair reproductive function in male rabbits by 
interfering with sex hormone profiles. 
 
Bentur et al. (2008) conducted a prospective observational study on the side effects 
of cathinone capsules (200 mg, marketed in Israel as a natural stimulant and 
aphrodisiac). The data of 34 patients aged between 16-54 years were analyzed. The 
results showed that the main clinical symptoms were hypertension, headache, 
vomiting, nausea, tachycardia, dyspnoea, myalgia and chest pain. The main 
complications were pulmonary edema, intracerebral haemorrhage and myocardial 
ischemia, all in young subjects. The study concluded that exposure to synthesized 
cathinone was associated with serious cardiovascular and neurological toxicity. 
 
In light of the above studies, it seems that the sexual behavior is influenced by the 
source of alkaloid used, dose level and mode of administration. When pure, 
chemically synthesized alkaloids particularly cathinone was given parenterally or 
orally, severe side effects are observed. However, moderate side effects are 
associated with ingestion of khat leaves. Low doses of khat-extract enhanced the 
sexual motivation of male rats more than sexual performance, while high doses 
produced opposite effects on both sexual motivation and performance. Also, the 
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positive effect of khat on sexual desire is more frequently observed in females than 
in males. It seems that khat is more effective on the sexual motivation/arousal or 
libido, particularly in females. Studies on the effect of khat on sexual behavior were 
summarized in Table (1.1).  
 11 
Table 1.1: Summery of studies on the effect of khat on sexual behavior. 
Reference Effects Compound Dose 
Mode of 
administr
ation 
Dura
tion 
Subject Side effects 
(Kervingant, 
1959) 
Aphrodisiac  khat - - - - - 
(Trellu, 1959) Aphrodisiac  khat -    ↓ desire 
(Halbach, 1972) 
Aphrodisiac  
↑  libido initially 
- - - - - 
spermatorrhoea and 
subsequent impotence 
may occur in a chronic 
use of khat. 
(Luqman and 
Danowski, 
1975) 
Aphrodisiac  
↑ sexual activity in 
depressed person 
↓ ejaculation, treats 
premature ejaculation 
Khat - Chewing - - 
a spontaneous secretion 
of spermatic fluid may 
occur in many khat 
chewers, when khat 
exacerbate or 
accentuate anxiety 
states 
(Chanoit et al., 
1980) 
- - - - - - 
Chronic administration 
of khat is believed to 
have a spermatorrhea in 
males. 
(Elmi, 1983) 
↑ female sexual desire 60% 
↑ male sexual desire 40% 
Khat - Chewing - Humans 
inability to sustain male 
erection   
(Islam et al., 
1990) 
Level change of Testosterone (%) 
(mg/kg) 5 10 30 
(-)-Cathinone ↑ 5 ↓28 ↓43 
(+)-Cathinone 0 0 ↓32 
 
5, 10 &  30  
mg/kg 
Intraperito
neal 
injection 
15 
days 
24 male 
Wistar 
rats 
(-)-Cathinone in rats 
showed a decrease in 
sperm count, an 
increase in number of 
abnormal sperms and a 
decrease in plasma 
testosterone.  
(Kalix, 1990) 
 
↑ libido Khat -  Chewing - - Spermatorrhoea 
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(Tariq et al., 
1990) 
% of change in 
(-)-Cathinone (mg/kg) 
5 10 30 
Sperm count  ↑ 5 ↓-21 ↓-28 
Sperm motility ↓-25 ↓-38 ↓-40 
Abnormal sperm ↑ 49 ↑ 106 ↑ 154 
 
5, 10 &  30  
mg/kg 
Intraperito
neal 
injection 
15 
days 
rats 
↓ Food and water 
intake 
(Giannini et al., 
1992) 
 Aphrodisiac  Khat - - - - - 
(Taha et al., 
1995) 
↑ sexual motivation 
↑ mounting performance   
Cathinone + 
caffeine 
5 + 50 
mg/kg/day) 
Oral 
15 
days 
male rats  
anogenital investigatory 
behavior with no 
stimulatory effect on 
erectile and ejaculatory 
responses. 
(Adeoya-
Osiguwa and 
Fraser, 2005) 
↑ Capacitation 
↑ Fertility 
Cathine-HCl 
Norephedrine-
HCl 
0.01–10 
mmol/L 
Incubation 1 h 
uncapacitated sperm suspensions of 
mouse and human spermatozoa 
(Mwenda et al., 
2006) 
↑ Testosterone  
↓ Prolactin and cortisol  
250g khat 
leaves  blended 
with water → 
juice 
juice 
(50mL/baboon) 
Oral month Baboons - 
(Abdulwaheb et 
al., 2007) 
Low dose  
↑ sexual motivation 
Low dose + ethanol  
↑ sexual motivation 
khat extract 
Low dose  
200mg/kg/day 
High dose 
400mg/kg/day 
Orally by 
gavage 
- male rats  
Low dose 
↓ mounting latency 
↓ intromission latency 
High dose  
↓ sexual motivation 
(Nyongesa et 
al., 2007) 
 Low dose,  
↑ testosterone  
No effect on interstitial cell 
viability 
khat extract  
Low dose 
0.06-6 mg/mL 
High dose 
30-60 mg/mL 
Cells 
incubated 
in khat 
extract 
- 
Isolated 
mouse 
interstitial 
cells 
High dose  
↓ testosterone  
↓ viability of interstitial 
cell 
(Nyongesa et 
al., 2008) 
↓ Luteinizing  
↓ Testosterone  
↑ Cortisol  
in a dose-dependent manner 
khat extract  
1.5, 4.5, 13.5, 
40.5 g/kg  
fed 
5 
weeks 
Rabbits  
Impair reproductive 
function in male rabbits 
by interfering with sex 
hormone profiles. 
(Bentur et al., 
2008) 
 Aphrodisiac  cathinone 200mg 
Oral 
capsules 
- - 
Serious neurological 
and cardiovascular 
complications,  
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1.2.5  ANOREXIC ACTIVITY OF KHAT 
Anorexia, a characteristic effect of khat has been used for centuries to alleviate the 
sensation of hunger (Feyissa and Kelly, 2008). However, the anorectic effect of khat 
was only studied in the last 30 years (Table 1.2). Due to the relatively complex 
extraction method from the khat plant, chemically synthesized alkaloid was 
investigated (Halbach, 1972; Kalix, 1990).  
 
The synthesized alkaloid was reported to possess anorexic properties and body 
weight reducing activity in animals. These alkaloid include (-)cathinone and 
(+)cathine (Knoll, 1979), phenylpropanolamine and alpha-aminopropiophenone 
(Zelger and Carlini, 1980), dl-cathinone (Foltin and Schuster, 1983; Woolverton and 
Johanson, 1984), dl-cathinone oxalate (Goudie and Newton, 1985), d-
norpseudoephedrine-HCl and dl-norephedrine-HCl (Eisenberg et al., 1987), 
cathinone-HCl (Nencini et al., 1988), (-)-cathinone and (+)-cathinone (Islam et al., 
1990), norpseudoephedrine (Nencini et al., 1996) or dl-cathinone-HCl (Wolgin and 
Munoz, 2006).  
 
In those studies, the alkaloids were mainly given parenterally, for example 
intraventricularly (Knoll, 1979), intraperitoneally (Zelger and Carlini, 1980; Foltin 
and Schuster, 1983; Woolverton and Johanson, 1984; Goudie and Newton, 1985; 
Eisenberg et al., 1987; Nencini et al., 1988; Islam et al., 1990; Nencini et al., 1996; 
Wolgin and Munoz, 2006) or intravenously (Schuster and Johanson, 1979; Yanagita, 
1979).  
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Schuster and Johanson (1979) investigated the behavioral effects of dl-cathinone and 
l-cathinone in rhesus monkeys and rats. They concluded that dl-cathinone served as a 
positive food reinforce when given intravenously in drug self-administration 
experiments. When connected to surgical indwelling venous catheters, caused a 
decrease in milk intake and produced tolerance to the anorexic effects.  
 
Foltin and Schuster (1982) examined the effects of dl-cathinone (0.25-48 mg/kg) on 
milk intake in rats. The study was conducted before, during and after a period of 
repeated daily dose given intraperitoneally. The results indicated a transient 
reduction in water intake followed by tolerance and
 
supersensitivity.  
 
Goudie and Newton (1985) compared the potency between dl-cathinone-oxalate and 
d-amphetamine sulphate on the conditioned taste aversion (reduced food intake) and 
adipsia (reduced water intake) in rats. The results showed that the potency ratio of dl-
cathinone to d-amphetamine for inducing conditioned taste aversion was 1:17 and 
adipsia was 1: 4. 
 
Wolgin and Munoz (2006) investigated the effects of dl-cathinone-HCl (2, 4, 8, 16 & 
32 mg/kg) given intraperitoneally on milk intake and motor activity in bottle- and 
cannula-fed rats. The study suggested that cathinone suppresses intake by inducing 
locomotion and stereotypy, which interfere with the appetitive phase of feeding, and 
tolerance to drug-induced hypophagia (reduced food intake) involves learning to 
suppress such movements (Wolgin and Munoz, 2006). 
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Methanolic khat extract administered orally by gavage to rats during days 6 to 15 of 
gestation at doses of 0, 125, 250 and 500 mg/kg/day reduced the food consumption 
and maternal weight gain and also lowered the food efficiency index, as compared to 
control mothers. The study revealed that khat retarded fetal growth, possessed both 
dose-related embryotoxic and teratogenic properties (Islam et al., 1994).  
 
Al-Habori and Al-Mamary (2004) investigated the long term (6 months) effects of 
khat leaves on the plasma concentration of triglycerides and cholesterol of animal 
rabbits. The results showed that there were significant decreases in plasma 
cholesterol and triglycerides levels. 
 
Administering fresh juice made of khat leaves, peeled bark and water to male baboon 
(250g/50 mL/baboon) decreased their mean body weight by as much as 10% 
(Mwenda et al., 2006).  
 
Hundred human male volunteers involved in a study, where 50 was control, 25 
chewed 200 g of khat leaves and 25 chewed 400 g of khat leaves. The result showed 
that the plasma leptin and non-esterified fatty acids were significantly increased in 
the group receiving 400 g of khat leaves, while plasma triglycerides were 
significantly decreased in both groups receiving khat leaves (Al-Dubai et al., 2006). 
 
Murray et al. (2008) showed that chewing of khat for a period of 3 h by six habitual 
khat chewers caused a significant decrease in the subjective feelings of hunger and 
increase in the fullness but had no effect on orexigenic ghrelin and anorexigenic 
peptide PYY. Normally, the orexigenic ghrelin is present in the stomach, its level 
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increases in time of hunger to increase appetite and decreases immediately post-meal 
to decrease appetite. On the other hand, the anorexigenic peptide YY is present in the 
intestine, its level increases following a meal to decrease appetite (Gale et al., 2004). 
 
1.2.6 SIDE EFFECTS OF KHAT 
The associated side effects were investigated by numerous studies. A medical survey 
carried out with 751 users and non-user of khat  reported that the common adverse 
effects of khat use are gastritis, insomnia, anorexia, constipation, headache, and 
respiratory difficulties (Kennedy et al., 1983).  
 
The effect of tube feeding of khat leaves to eight awake, chronically catheterized, 
late-pregnant guinea pigs suggested a reduction in placental blood flow and 
impairment in fetal growth (Jansson et al., 1988). 
 
The effects of repeated oral administration of khat or the commercial S-(-)-cathinone 
enhanced aggression in rats, presumably by decreasing the serotonin and its 
corresponding metabolite levels. These effects were produced by dose levels of S-(-)-
cathinone-HCl at 1.5 mg/kg and fresh-khat-extract at 200 mg/kg (Banjaw et al., 
2006).  
 
Al-Motarreb et al. (2002a) reported that chewing of fresh khat leaves resulted in 
acute myocardial infarction. Kuczkowski (2005) documented two cases of chest pain, 
tachycardia and hypertension in two pregnant patients who used fresh khat in 
familial gatherings. Mujlli et al. (2005) reported that khat is a risk to blood pressure 
in acute cerebral infarction patients. However, all the above studies did not consider 
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the adjustment of the confounding effects of smoking (since 80% of khat chewers are 
smokers). As such, their findings might be due to either khat chewing or both khat 
chewing and smoking habits (Al-Hebshi and Skaug, 2005).  
 
Pennings et al. (2008) stated that the level of abuse  and threat to public health of the 
green vegetables’ khat leaves are not significantly enough to warrant international 
control. In addition, epidemiological studies over the last 50 years (1945–2006) 
reviewed by Warfa et al. (2007) did not support a causal relationship between khat-
chewing and mental illness.  
 
In light of all the above studies, it seems that the chemically synthesized alkaloids 
possess anorexic, body weight reducing properties and many other associated side 
effects. The severity of these side effects is influenced by the source of alkaloid used, 
dose level and mode of administration. When pure alkaloid particularly cathinone 
was given parenterally (intraperitoneally, intraventricularly or intravenously), severe 
side effects are observed. However, moderate side effects are associated with 
ingestion of khat leaves.  
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Table 1.2: Comparison between studies on the effect of khat on body weight, loss of appetite (anorexia), triglycerides, cholesterol or lipolysis 
Reference Effects Compound used 
Mode of 
administration 
Dose 
Treatment 
period 
Experimental 
subject 
Side effects 
(Knoll, 1979) ↓F.I 
(-) Cathinone 
(+) cathine 
Intraventricular - - rats - 
(Schuster and 
Johanson, 1979) 
Positive food reinforce 
↓ milk intake in rats 
dl- Cathinone,  
l-Cathinone &  
d-amphetamine 
Intravenous 
Injection 
- - 
3 Rhesus 
monkeys 
& Rats 
Tolerance to its 
anorexic effects 
(Yanagita, 1979) - 
l-cathinone, 
dl-cathinone, 
dl-ephedrine, 
d-amphetamine 
d-norpseudoephedrine 
Intravenous 
Injection 
- 1 mg/kg 
- 10-5g/ml 
- 0.06-0.25 
mg/kg 
/injection 
- 1 h 
- 1 h 
- Month 
- anesthetized 
rats 
- isolated 
guinea pig 
atria 
- 2 Rhesus 
monkeys 
- ↑ Blood pressure,  
↑ heart rate 
- Ionotropic 
- Drug self 
administration 
(Zelger and Carlini, 
1980) 
↓ B.W 
Anorexia 
Phenylpropanolamine 
α-aminopropiophenone 
Intraperitoneal 
injection 
- - rats - 
(Foltin and 
Schuster, 1982) 
↓F.I  25% dl-Cathinone 
Intraperitoneal 
injection 
4 mg/kg Month 
20 SD male 
Rats 
transient nature of the 
tolerance and
 
supersensitivity after 10 
days 
(Kennedy et al., 
1983) 
Anorexia Khat leaves Chewing - - Humans 
constipation, insomnia, 
headaches, respiratory 
difficulties 
(Goudie and 
Newton, 1985) 
Anorexia dl-Cathinone oxalate 
Intraperitoneal 
injection 
1, 4 & 16 
mg/kg 
Month rats 
- Taste aversion 1:17 
(dl-cathinone : d-
amphetamine) 
- Adipsia (1: 4) 
(Eisenberg et al., 
1987) 
AD50 (50% ↓ F.I) 
NPE = 22 mg/kg 
NE = 18 mg/kg 
phenylpropanolamine 
d-Norpseudoephedrine-
HCl 
dl-Norephedrine-HCl 
Intraperitoneal 
injection 
10-50 mg/kg 1 day 
24 SD male 
Rats 
NPE increase 
locomotor activity. 
(Nencini et al., Acute: - ↓F.I Cathinone-HCl Intraperitoneal 2, 4 or 8 Month 48 SD male - Tolerance after 9 days 
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1988) Chronic: ↑ W.I injection mg/kg Rats - diuresis 
(Jansson et al., 
1988) 
↓F.I Khat leaves Feeding 2.2 g/kg 10 days 
Pregnant 
guinea pigs 
↓ Birth weight (7%) 
(Islam et al., 1990) 
5, 10 &  30  mg/kg 
(-)-Cathinone 
↓F.I: 27,44 & 72% 
↓W.I: 3,19 &25% 
↓B.W: 15,28 &40% 
(+)-Cathinone 
↓F.I: 6,11& 50% 
↓W.I: 0,19 &26% 
↓B.W: 28,36&42% 
(-)-Cathinone 
(+)-Cathinone 
Intraperitoneal 
injection 
5, 10 &  30  
mg/kg 
15 days 
24 male Wistar 
rats 
(-)-Cathinone: 5, 10 & 
30 mg/kg 
Testosterone: ↑ 5, ↓28 
& ↓43% 
 
(+)-Cathinone: 5, 10 & 
30 mg/kg 
Testosterone: 0, 0 & 
↓32% 
(Brenneisen et al., 
1990) 
- Cathinone-HCl Oral capsules 0.5 mg/kg One day 6 humans 
↑ Blood pressure, ↑ 
heart rate 
(Islam et al., 1994) 
↓F.I 
↓ B.W 
↓ Food efficiency 
 
Methanol khat extract 
Orally by 
gavage 
125, 250 & 
500 mg/kg 
6-15 days rats 
- ↑ resorptions & fetal 
wastage. 
- Intrauterine growth 
retardation. 
- embryotoxic & 
teratogenic. 
(Nencini et al., 
1996) 
↓F.I Norpseudoephedrine 
Intraperitoneal 
injection 
17, 32 & 56 
mg/kg 
6 days SD Rats 
Antidipsic ↓water 
intake 
(Griffiths et al., 
1997) 
Anorexia 
↓ B.W 
Khat Chewing - - Humans 
- Trouble sleeping 
- Feeling depressed 
- Mood swings 
- Feeling anxious 
 
(Al-Habori and Al-
Mamary, 2004) 
↓Cholesterol 
↓Triglycerides 
Dried khat leaves 
added to the 
diets 
20 & 30% of 
food/rabbit 
6 months Rabbits - 
(Wolgin and 
Munoz, 2006) 
↓F.I dl-Cathinone-HCl 
Intraperitoneal 
injection 
2, 4, 8, 16, & 
32 mg/kg 
2 weeks SD Rats 
- Tolerance (less than 
amphetamine). 
- Cathinone induced 
sensitization of 
hypophagia in saline-
treated controls (not 
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found with 
amphetamine). 
(Mwenda et al., 
2006) 
↓ B.W (10%) 
250g khat; leaves & 
shoots removed and 
bark peeled was 
blended with water → 
juice 
Oral 
Juice (50mL/ 
baboon) 
month baboons - 
(Al-Dubai et al., 
2006) 
Anorexia 
↓ B.W 
↓Triglycerides 
 
Khat leaves Chewing 
200-400g 
leaves/person 
one day humans - 
(Warfa et al., 2007) Anorexia - - - - - 
- Minor psychosis due 
to cathinone 
(Hassan et al., 
2007) 
Anorexia - - - - - 
- Psychosis due to 
cathinone 
- ↑ Blood pressure 
- Hypertension 
- Constipation 
(Murray et al., 
2008) 
Anorexia Fresh Khat leaves 
leaves chewed 
but not 
swallowed 
200-400 g of 
leaves / 
person 
3 h 
6 men habitual 
khat chewer 
- 
(Feyissa and Kelly, 
2008) 
↓ F.I 
↓ B.W 
- - - - - 
- Minor psychosis due 
to cathinone 
- Aggression due to 
cathinone 
- Food-reinforced 
(Pennings et al., 
2008) 
↓Cholesterol 
↓Triglycerides 
↓F.I 
↓ B.W 
↓ Food efficiency 
- - - - - 
- Acute myocardial 
infarction 
- Tachycardia & 
Hypertension 
- ↑ Blood pressure 
F.I (Food Intake), B.W (Body Weight), W.I (Water Intake) 
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1.3 CONTROLLED RELEASE DRUG DELIVERY SYSTEM 
The controlled-release drug delivery is defined as dosage form that allows reduction 
in dosing frequency or significant increase in patient compliance or therapeutic 
performance when compared with that presented as a conventional dosage form. The 
rationale for development of controlled-release formulation of a drug is to enhance 
its therapeutic benefits, minimizing its side effects while improving the management 
of the diseased condition (Tiwari and Rajabi-Siahboomi, 2008). 
 
1.3.1 MICROCAPSULES  
Microcapsules are small particles (3-800 μm) that contain an active agent or core 
material (10-90 wt%) surrounded by a coating or shell (Thies, 2006). The core 
material can be consisting of single or multiple compounds with hydrophilic and/or 
hydrophobic properties and the coat can be matrix, single layer or multilayer, and can 
be hydrophilic and/or hydrophobic (Benoit et al., 2006). The choice of coating 
materials depends on the physicochemical properties of the core materials (Magdassi 
and Vinetsky, 2006). If a water-insoluble core material is dispersed in the system and 
the coacervate wets this core material, each droplet or particle of dispersed core 
material is spontaneously coated (Thies, 2006). A complex system of multiple 
emulsions could be used in microencapsulation of single or multiple aqueous 
compartments with hydrophilic/hydrophobic variation (Garti and Aserin, 2006). 
However, the composition ratio entrapped into microcapsules could be negatively 
affected by the core partition problem. 
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1.3.2 CORE PARTITION PROBLEM IN MICROENCAPSULATION 
PROCESS 
The core partition effect is the major problem encountered in microencapsulation of 
water soluble drugs. Several studies highlighted the importance in resolving the core 
partition effect. One of the solutions reported was dispersion of drug (with or without 
polymer) into non-aqueous dispersion medium, e.g. oil or non-aqueous solvents (to 
prevent drug loss) and emulsification as a w/o emulsion with or without the polymer 
(aqueous or non-aqueous) (Chang and Roland, 1996; Sriwongjanya and Bodmeier, 
1997; Kedzierewicz et al., 1999; Nokhodchi and Farid, 2002; Wieland-Berghausen et 
al., 2002). However, non-aqueous medium is often expensive, requires recycling and 
difficult to eliminate (Benoit et al., 1996). In addition, emulsification of the drug into 
an emulsion (o/w) produces irregular and rough surfaces (Cruaud et al., 1999). This 
might be attributed to drug partitioned into the external phase (aqueous) and drug 
crystals deposited on the outer layer of the microsphere. In another study, drug was 
encapsulated by wax using spray congealing (Passerini et al., 2003). As a result of 
the wetting difficulty between the highly hydrophilic drug crystals and the highly 
lipophilic molten wax, a limited loading was obtained even after the addition of 
surfactants. Encapsulation of water-soluble drugs was further improved by using 
w/o/w double emulsion (Freytag et al., 2000; Hombreiro Pérez et al., 2000). The 
amount of oil phase decreased, but lower encapsulation efficiency was reported due 
to the higher solubility of drug in the external aqueous phase. The comparatively 
higher volume compared to that of the internal aqueous phase caused leakage of drug 
into the continuous phase (Hombreiro Pérez et al., 2000) and the partition of drug 
into the external phase during the encapsulation process (Freytag et al., 2000). Some 
advances in decreasing the drug partition effect have been achieved by decreasing 
 23 
the drug solubility with initial emulsification of drug in an insoluble biodegradable 
polymer prior to emulsification into the double emulsion w/o/w (Meng et al., 2003; 
Ubrich et al., 2004), or by covering a single hydrophilic core with a thin 
biodegradable polymer membrane using the ink-jet-interfacial phase separation 
method (Yeo et al., 2003), or layering a drug (22%) into a binder solution [80% 
(HPMC, PEG, ethanol, and water)] prior to coating with biodegradable polymer film 
(Lecomte et al., 2004). Alternatively, the initial drug-containing water phase was 
separated from the dispersion medium by the lecithin-containing oil phase which was 
advantageous in maintaining encapsulation efficiency of the water-soluble drug (Nii 
and Ishii, 2005). Recent studies were conducted to separate drug from the aqueous 
phase and/or from the oily continuous phase prior to preparing the double emulsion 
either by decreasing the drug’s water solubility or by solidifying the drug in the 
phase to prevent drug migration from one phase to another (Hasan et al., 2007; Puri 
et al., 2008; Cohen-Sela et al., 2009). Such studies prevented the rapid partitioning of 
drug into the external phase, but the excess material used with a low drug percentage 
and total loading capacity could be limited. Capacity of loading was usually 
increased through supercritical anti-solvent or electrospinning process methods using 
biodegradable polymers (Lee et al., 2006; Qi et al., 2008), culturing of drug into 
yeast cells (Shi et al., 2007), gelatin complex coacervation method (Jin and Kim, 
2008), or using hydrogen peroxide to make porous microspheres with a thin layer to 
cover the surface (Bae et al., 2009). In short, it can be concluded that the water 
soluble cores can be microencapsulated by complicated procedures with various 
limitations (Tables 1.3 and 1.4).  
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Table 1.3: Studies conducted for resolving the core partition effect in microencapsulation of water soluble drugs 
Reference Core Coat Method Outcome Disadvantages 
(Chang and 
Roland, 1996) 
- Propranolol HCl 
- Ethylcellulose 
pseudolatexes 
 
- Eudragit RS 30D 
 
w/o emulsion 
- Microspheres prepared from water-insoluble 
polymers without use of organic solvents. 
- Drug-polymer was dispersed into external oil 
phase, emulsified, microspheres collected by 
filtration, washed with hexane to remove 
excess oil from the microsphere surface, and 
dried under vacuum in a desiccator overnight.  
- Difficulty of collecting and drying 
of microspheres from the oil 
phase (cottonseed oil). 
- Washing microspheres with 
hexane. 
 
(Sriwongjanya 
and Bodmeier, 
1997) 
- Chlorpheniramine 
maleate 
- Pseudoephedrine 
HCI 
- Propranolol HCl 
 
- Ethylcellulose 
- Poly (methyl 
methacrylate) 
- Eudragit RS 100 
 
Aqueous solvent 
evaporation 
 
Drug was bound to resin, dispersed in an 
organic polymer solution and followed by 
emulsification into an external aqueous phase. 
- Complicated, long procedures and 
excess materials were used. 
- The optimum microparticles 
selected was produced at ratios of 
(drug) to (resin) to (polymer) to 
(surfactant) of (0.5-1) :(1) : (4) : 
(0.1-1) respectively, which the 
theoretical drug loading % could 
be less than 15%. 
(Cruaud et al., 
1999) 
- Baclofen 
 
- Poly(lactic-co-
glycolic acid) 
o/w emulsion 
extraction 
Microspheres exhibiting smooth surfaces at 
low drug payload (12.8% w:w), irregular and 
rough surface at high drug content (33.9% 
w:w) 
 
- The irregular and rough surface 
produced at high drug content 
was due to the using of o/w 
emulsion, drug partitioned to the 
external phase (aqueous) and 
after drying the drug crystallized 
on microsphere surface.  
- Methylene chloride used to 
dissolve PLGA 
- Lower encapsulation efficiency   
(Kedzierewicz 
et al., 1999) 
- Propranolol HCl 
- Gellan gum 
 
 
 Ionotropic gelation 
 
Beads were prepared by solubilising the drug 
in a dispersion of gellan gum and then 
dropping the dispersion into calcium chloride 
solution. 
- Entrapment efficiencies (92%) 
and slow release were pH 
dependent 
-  Lower drug loading; drug (12.5-
100 mg) to polymer 1g 
(Nokhodchi - Paracetamol - Cellulose acetate  Emulsion solvent Paracetamol was dispersed into liquid paraffin - Acetone was used for dissolving 
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and Farid, 
2002) 
 phthalate evaporation 
Modified emulsion 
solvent evaporation 
Emulsion non-solvent 
addition 
 
or liquid paraffin hexane mixture, emulsify, 
liquid paraffin was decanted, and 
microcapsules were collected, washed twice 
with 50 mL of chloroform to remove any oil 
remaining and dried under reduced pressure for 
at least 12 h. 
of polymer  
- Chloroform and hexane used as 
non-solvent 
- Liquid paraffin as dispersion 
medium. 
- Difficulty of collecting and drying 
of microcapsules from the oil 
phase (liquid paraffin). 
- Washing microcapsules with 
chloroform.  
(Wieland-
Berghausen et 
al., 2002) 
- Nitenpyram 
Clomipramine HCl 
 
- Ethylcellulose 
- Eudragit EPO 
- Eudragit E 
- Coacervation 
- Solvent evaporation 
(w/o) 
- Film-coating 
 
- Oppanol B50  was used as 
coacervating agent and 
cyclohexane was used as 
dispersion medium  
- Acetone was used to dissolve 
Eudragit E 
- Acetone was used to dissolve 
Eudragit EPO 
(Meng et al., 
2003) 
- Blank 
microparticles for 
loaded of lysozyme 
PELA 
 
- w/o/w double 
emulsion solvent 
diffusion 
 
- Using ethyl acetate 
(Passerini et 
al., 2003) 
- Verapamil HCl  Wax - spray congealing 
Low encapsulation efficiency was explained by 
difficult wetting of the highly hydrophilic drug 
crystals by the highly lipophilic molten wax.  
But addition of a surfactant (Stearyl alcohol 
90) was improved drug wettability, enhances 
the release and increased the encapsulation 
efficiency. 
 
The % of drug loaded was 10% 
which is low. 
(Yeo et al., 
2003) 
- Sodium alginate 
 Poly(lactic-co-
glycolic acid) 
- Ink-jet 
- Interfacial phase 
separation 
Thin biodegradable polymer membrane 
covering a single hydrophilic core 
Ethyl acetate 
 
(Lecomte et 
al., 2004) 
- Propranolol HCl 
Ethyl cellulose 
 Eudragit L 
 PEG 
- Film coating 
Formulation of propranolol-HCl into sustained 
release pellets   
- Complicated, long procedures and  
- Excess materials (polymers, 
plasticizers) were used. 
